A5019494133- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Cancer survivorship and care
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Family Support in Illness
- Economic and Financial Impacts of Cancer
- Palliative Care and End-of-Life Issues
- Hemoglobinopathies and Related Disorders
- T-cell and B-cell Immunology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Biomedical Ethics and Regulation
- Prenatal Screening and Diagnostics
- Adolescent and Pediatric Healthcare
Sarah Cannon
2022-2025
Centennial Medical Center
2022-2025
Cleveland Clinic
2014-2024
Case Comprehensive Cancer Center
2002-2024
Case Western Reserve University
2017-2023
Cleveland Clinic Lerner College of Medicine
2017-2022
University School
2020-2022
Hospital for Sick Children
2021
Penn State Milton S. Hershey Medical Center
2021
University of Central Florida
2021
Purpose Allogeneic hematopoietic cell transplantation (HCT) is curative but associated with life-threatening complications. Most deaths occur within the first 2 years after transplantation. In this report, we examine long-term survival in 2-year survivors largest cohort ever studied. Patients and Methods Records of 10,632 patients worldwide reported to Center for International Blood Marrow Transplant Research who were alive disease free receiving a myeloablative allogeneic HCT before 2004...
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. With advances technology and supportive care practices, HCT has become safer, patient survival continues to improve over time. Indications for continue evolve as research refines role established indications identifies emerging where may be beneficial. The American Society Blood Marrow Transplantation (ASBMT) a multiple-stakeholder task force consisting of transplant experts,...
Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) older patients using less intense conditioning regimens also contributed an increase the number HCT survivors. These survivors are at risk developing late complications secondary pre-, peri-, posttransplantation exposures factors. Guidelines...
Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival population-based cohort.The included 38,060 malignancies or disorders who underwent first alloHCT US Canadian center from 1994 to 2005 were reported Center International Blood Marrow Transplant Research.AlloHCT treatment acute lymphoblastic (ALL) myeloid leukemias (AML),...
Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of transplant survivors. To adequately support their healthcare needs, there is a need know the prevalence HCT We used data on 170,628 recipients autologous and allogeneic reported Center for International Blood Marrow Transplant Research from 1968 2009 estimate current future survivors United States. Stacked cohort simulation models were States make projections by year 2030. There 108,900 (range, 100,500...
Peripheral blood progenitor cell mobilization practices vary significantly among institutions. Effective regimens include growth factor alone, chemotherapy and combined, and, more recently, incorporation of plerixafor with either approach. Many institutions have developed algorithms to improve stem success rates cost-effectiveness. However, an optimal regimen has not been defined. Practical guidelines are needed address important clinical questions, including which is optimal, what dose most...
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications transplantation, availability alternative donor sources, less toxic preparative regimens, new manipulation techniques, novel GVHD prevention methods, all which have expanded the applicability procedure. These advances led to clinical practice conundrums when...
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications international access improves, the number of HCTs performed annually continues rise. Parallel improvements in HCT techniques supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary pretransplantation, peritransplantation, post-transplantation exposures other underlying factors....
We conducted a study to evaluate the role of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) in detection distant metastases from renal cell carcinoma (RCC).Twenty-four patients with histologically proven clear-cell RCC undergoing surgical evaluation for possible resection recurrent disease were investigated. All had suspected based on conventional anatomic imaging techniques (computed and magnetic resonance imaging). A total 36 metastatic sites identified. Pathology all was...
Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy for primary refractory (PR REF) or relapsed (REL) Hodgkin's lymphoma (HL); however, more than half of these patients eventually relapse and die their disease. We studied long-term outcomes evaluated factors influencing progression-free survival (PFS) in 141 with PR REF REL HL who underwent ASCT between 1985 2003. Median age at was 30 years (range, 7–60 years); 21 had REF, 120 HL. With a median follow-up 6.3...
Success of hematopoietic cell transplantation (HCT) can vary by race, but the impact socioeconomic status (SES) is not known. To evaluate role race and SES, we studied 6207 unrelated-donor myeloablative (MA) HCT recipients transplanted between 1995 2004 for acute or chronic leukemia myelodysplastic syndrome (MDS). Patients were reported transplant center to be White (n = 5253), African American 368), Asian/Pacific-Islander 141), Hispanic 445). Patient income was estimated from residential...
The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive from participating centers were analyzed, and based on clinical status response inhibitors at the time HCT, stratified into 5 groups: (1) improvement (n = 23),...
Abstract BACKGROUND: The purpose of the current study was to determine whether use hematopoietic stem cell transplantation (HCT) treat leukemia, lymphoma, or multiple myeloma (MM) differs by race and sex. METHODS: annual incidence MM estimated in United States people aged <70 years sex using Surveillance, Epidemiology, End Results (SEER) cancer registry between 1997 2002 US census reports for year 2000. autologous, human leukocyte antigen (HLA) identical sibling, unrelated HCT performed...